For research use only. Not for use in humans.
Favezelimab (Anti-LAG3 / CD223)
Synonyms: MK-4280
Favezelimab (Anti-LAG3 / CD223) is a humanised monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW: 145.98 KD.
Quality Control
Specificity
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.
2. "✔" indicates inhibitory effect, but without specific value.
Mechanism of Action
| Description |
Favezelimab (Anti-LAG3 / CD223) is a humanised monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW: 145.98 KD.
|
References |
|---|
Product Details
| CAS No. | 2231068-83-8 |
|---|---|
| Molecular Weight | 145.98 |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
Comparison of Clones for
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tech Support
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.